COVID-19 Vaccine Booster Dose Willingness among Patients with Inflammatory Bowel Disease on Infliximab and Vedolizumab: A Cross-Sectional Study

Background: Vaccination has been effective in preventing COVID-19 infections and related mortality. However, waning immunity after two-dose vaccination prompted health authorities to recommend a third dose of COVID-19 vaccine to boost immunity. The aim of our study was to assess willingness to recei...

Descripción completa

Detalles Bibliográficos
Autores principales: Shehab, Mohammad, Alrashed, Fatema, Alfadhli, Ahmad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331669/
https://www.ncbi.nlm.nih.gov/pubmed/35893815
http://dx.doi.org/10.3390/vaccines10081166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331669/
https://www.ncbi.nlm.nih.gov/pubmed/35893815
http://dx.doi.org/10.3390/vaccines10081166

Ejemplares similares